MicroRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5

Lihui Yu, Ying Lu, Xiaocui Han, Wenyue Zhao, Jiazhi Li, Jun Mao, Bo Wang, Jie Shen, Shujun Fan, Lu Wang, Mei Wang, Lianhong Li, Jianwu Tang, and Bo Song

Abstract

Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. microRNA-140-5p (miR-140) has been shown to be involved in cartilage development and osteoarthritis (OA) pathogenesis. Some contradictions still exist concerning the role of miR-140 in tumor progression and metastasis, and the underlying mechanism is uncertain.

Methods: Immunohistochemistry was performed to determine the expressions of ADAMTS5 and IGFBP5 in CRC tissues. Human CRC cell lines HCT116 and RKO were transfected with miR-140 mimic, inhibitor, or small interfering RNA (siRNA) against ADAMTS5 or IGFBP5, respectively, using oligofectamine or lipofectamine 2000. Scratch-wound assay and transwell migration and invasion assays were used to evaluate the effects of miR-140 on the capabilities of migration and invasion. The levels of miR-140 and ADAMTS5 and IGFBP5 mRNA were measured by quantitative real-time polymerase chain reaction (qRT-PCR). Western blot was performed to examine the expression of ADAMTS5 and IGFBP5 proteins.

Results: miR-140 was significantly reduced, whereas ADAMTS5 and IGFBP5 were upregulated, in the human CRC tissues compared to the corresponding normal colorectal mucosa. miR-140 downregulation and ADAMTS5 or IGFBP5 overexpression were associated with the advanced TNM stage and distant metastasis of CRC. There was a reverse correlation between miR-140 levels and ADAMTS5 and IGFBP5 expression in CRC tissues. ADAMTS5 and IGFBP5 were downregulated by miR-140 at both the protein and mRNA levels in the CRC cell lines. The gain-of- and loss-of-function studies showed that miR-140 inhibited CRC cell migratory and invasive capacities at least partially via downregulating the expression of ADAMTS5 and IGFBP5.

Conclusions: These findings suggest that miR-140 suppresses CRC progression and metastasis, possibly through downregulating ADAMTS5 and IGFBP5. miR-140 might be a potential therapeutic candidate for the treatment of CRC.

Keywords: Colorectal cancer, microRNA-140-5p, ADAMTS5, IGFBP5, Invasion, Metastasis

© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Colorectal cancer (CRC) is one of the most common malignancies and the second most common cause of cancer deaths worldwide [1, 2]. Surgery with or without adjuvant radiation and chemotherapy treatments based on tumor stages have been recommended according to current guidelines. However, there are still patients with early surgery suffering from metastases, especially liver metastases, which can finally result in death [3]. Like other solid cancers, the development of CRC is a multi-step progression involving the activation of oncogenes and inactivation of tumor suppressor genes, which will affect all aspects of tumorigenicity of CRC, such as cell proliferation, apoptosis, invasion, and metastasis [4]. Because of the disease complexity, the specific molecular genetic and epigenetic alterations of CRC remain largely unknown.

MicroRNAs (miRNAs) are small (19–25 nucleotides), noncoding, regulatory RNAs that can negatively regulate gene expression by complementary base pairing with the 3’-untranslated region (UTR) of target messenger RNAs (mRNAs), leading to their degradation or repression of mRNA translation [5, 6]. Abnormal expression of miRNAs is suggested to be associated with various human disorders, including cancer, indicating that they play a critical role in the molecular mechanism of cancer pathogenesis and progression [7].

The gene encoding microRNA-140-5p (miR-140) is located in chromosome 16. It was first found as a cartilage-specific expression microRNA. Wen et al. [8] and Tuddenham et al. [9] reported that miR-140 was specifically expressed in cartilage tissues of zebrafish and mouse embryos, and later its downregulation was shown to play a critical role in the pathogenesis of osteoarthritis (OA) [10–12]. Importantly, several recent studies have revealed the functions of miR-140 in tumorigenesis. The results from our group showed that ectopic expression of miR-140 in human osteosarcoma and CRC cells can induce cell cycle arrest and inhibit cell proliferation, in part through the suppression of histone deacetylase 4 (HDAC4) [13]. In hepatocellular carcinoma (HCC), miR-140 was found to target TGFBR1 and FGF9, and its overexpression could suppress HCC growth and metastasis [14].

In non-small cell lung cancer (NSCLC), miR-140 can target the associated (MMD) to inhibit tumor growth and metastasis [15]. miR-140 inhibited esophageal cancer cell invasion by targeting slug and the subsequent epithelial-mesenchymal transition (EMT) process [16]. Additionally, several studies indicated that downregulation of miR-140 can promote cancer stem cell (CSC) formation in breast cancer and CRC [17–21]. However, some contradictions still exist concerning the role of miR-140 in tumor progression. Malzkorn et al. [22] reported that miR-140 is one of the increased microRNA candidates in glioma progression from grade II to grade IV. Gülüli et al. [23] also found that miR-140 is overexpressed in the invasive ductal breast cancer tissues and lymph node-positive samples. Based on the above studies, we intend to investigate the impact and mechanism of miR-140 on CRC progression.

A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family is a type of newly discovered, zinc-dependent secreted proteinase consisting of 19 members that share the metalloproteinase domain with matrix metalloproteinases (MMPs) [24]. Among ADAMTSs, ADAMTS5 (aggrecanase-2) is well known for its importance in cartilage destruction [24]. Recently, increasing evidence suggests that ADAMTS5 is involved in cancer development and progression. Nakada et al. [25] reported that ADAMTS5 is upregulated in human glioblastoma compared to the normal brain tissues and its overexpression can enhance the invasive capacity of glioblastoma cells. Matrigel contains birevican, a substrate for ADAMTS5. Another study showed that higher miR-140 expression of ADAMTS5 is found in the metastatic foci of head and neck cancer as compared to their corresponding primary tumors as well as normal tissue [26]. Filou et al. [27] reported that ADAMTS5 is the main type of aggrecanase expressed in the laryngeal squamous cell carcinoma (LSCC) and presents a stage-related increase. A more recent study reported that miR-144/451 inhibits breast cancer and head and neck squamous cell carcinoma (HNSCC) metastasis by targeting ADAMTS5 and ADAM10, and the overexpression of these two proteins being significantly associated with lymph node metastasis and pathological grade [28].

Insulin-like growth factor (IGF)-binding proteins (IGFBPs) are important regulators of the IGF signaling pathway which consists of six members [29]. IGFBP5, the most conserved member of the IGFBPs in all vertebrates, has been found to play a role not only in the physical processes, such as cell growth, death, and motility, but also in the pathologic processes such as cancer development and metastasis [30]. IGFBP5 promotes prostate cancer growth in vitro and in vivo [31–33]. The plasma levels of IGFBP5 are 1.5-fold higher in breast cancer-bearing mice than in nontumor-bearing mice and are positively correlated with the tumor size [34]. In a rat colon cancer model, IGFBP5 is among the most upregulated gene by microarray gene expression analysis [35]. Hao et al. [36] reported that the expression of IGFBP5 is increased in breast cancers with axillary lymph node involvement and lymph node metastatic tissues compared with primary breast cancer samples. Wang et al. [37] also found that IGFBP5 is more highly expressed in T1 invasive breast cancer than in normal breast epithelium. Moreover, T1N1 breast cancers are more likely to have moderate and strong positive staining for IGFBP5 than T1N0 cancers.
These data suggest that ADAMTS5 and IGFBP5 may promote the tumorigenesis and cancer progression. Very interestingly, Miyaki et al. [10] and Tardif et al. [38] have experimentally confirmed that ADAMTS5 and IGFBP5 are the direct targets of miR-140 in HEK293T cells and human OA chondrocytes, respectively. Our previous study has shown that miR-140 inhibits human osteosarcoma and CRC cell growth and is also involved in the chemoresistance to methotrexate and 5-fluorouracil (5-FU) [13]. In the current study, we investigated the suppressive role of miR-140 in CRC progression and the correlation with downregulating ADAMTS5 and IGFBP5.

Methods

Cell culture and reagents

The human CRC cell lines, HCT116 and RKO, were purchased from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China. HCT116 cells were maintained in McCoy’s 5A medium (Gibco) and RKO cells were cultured in MEM medium (Gibco) containing 10% fetal bovine serum (FBS; Gibco) in a 5% CO₂ container at 37 °C.

Clinical specimens

Sixty CRC patients admitted to the First Affiliated Hospital of Dalian Medical University, Dalian, China, were enrolled in this study. The use of human tissue samples was in accordance with relevant guidelines and regulations, and the experimental protocols were approved by the Medical Ethics Committee of the First Affiliated Hospital of Dalian Medical University. All patients have complete clinicopathological data. The adjacent normal colorectal tissue of each patient within at least 5 cm of the tumor margin [39] was also collected as the negative control. All patients provided written informed consent prior to participation in the study. The CRC specimens were histologically examined by hematoxylin and eosin (H&E) staining.

Transfections of the miRNA mimics and siRNAs specific for ADAMTS5 and IGFBP5

HCT116 and RKO cells (3 × 10⁵ per well) were plated in six-well plates and then transfected with 100 nM of either miRNA mimic or negative miRNA (Invitrogen) after 24 h with lipofectamine (Invitrogen) according to the manufacturer’s protocols, respectively. Small-interfering RNAs (siRNAs) specific for ADAMTS5 or IGFBP5 (siADAMTS5 or siIGFBP5) from Invitrogen were transfected with lipofectamine at a final concentration of 100 nM in Opti-MEM I Reduced Serum Medium (Life Technology) according to the manufacturer’s instructions. The transfected cells were harvested for RNA isolation and protein extraction at 24 h and 48 h after transfection, respectively.

miR-140 knockdown

To knock down the endogenous miR-140, HCT116 and RKO cells were transfected with 100 nM of scrambled miRNA inhibitor or miR-140 inhibitor by lipofectamine 2000 (Invitrogen) in six-well plates (3 × 10⁵ cells/well), respectively. The miRNA inhibitors were purchased from Invitrogen. Co-transfections of miR-140 inhibitor and siADAMTS5 or siIGFBP5 were the negative control. The transfected cells were harvested for protein extraction at 72 h post-transfection.

Scratch-wound assay

A scratch-wound assay was performed to evaluate the effect of miR-140 on CRC cell migration. The CRC cells (3 × 10⁵ cells/well) in six-well plates were transfected with miRNAs, miRNA inhibitors, or siRNAs and cultured until reaching confluence. A 10 μl pipette tip was used to scrape the monolayer cells for generating a scratch wound. The wounded surface was washed with 1 x phosphate-buffered saline (PBS) to remove the cell debris and thereafter cultured in the serum-free medium. At 72 h after scrape, the wound closures were photographed with a BZ-8100 microscope (Keyence, Japan).

Transwell migration and invasion assays

For the transwell invasion assay, 60 μl of matrigel was diluted with precooled serum-free medium in 1:4 ratios and was added to the bottom of the transwell chamber and incubated for 1 h at 37 °C. The parental and transfected cells were resuspended at the density of 1 × 10⁶ cells/ml after starvation for 24 h, then 200 μl of cell suspension (2 × 10⁵ cells) were seeded into the upper chambers (24-well insert; pore size 8 μm), while medium supplemented with 10% FBS (600 μl) was placed in the lower chamber. After incubation at 37 °C for 24 h, cells on the top side of the inserts were removed gently with a cotton swab. The inserts were then fixed by 4% formaldehyde for 15 min and stained with 0.1% crystal violet for 15 min. The average migratory cells were counted by randomly choosing five fields each time under the microscope. The experiments were repeated three times.

For the transwell migration assay, the remaining protocol was the same as the transwell invasion assay except for the pre-coat of the matrigel in the inserts.

RNA extraction

Total RNA, including miRNA, were isolated from the CRC cells with or without transfection and fresh frozen CRC tissues using TRIZol reagent (Invitrogen) according to the manufacturer’s instructions.

For human CRC, formalin-fixed, paraffin-embedded (FFPE) specimens, approximately 0.005 g for each sample, were extracted. These samples were deparaffinized with xylene, hydrated by ethanol, and digested with proteinase
K. Total RNA was isolated using the High Pure RNA Paraffin Kit (Roche, Germany) according to the manufacturer's instructions.

Quantitative RT-PCR
For quantitative real-time polymerase chain reaction (qRT-PCR) analysis of miRNA, cDNA was synthesized using the TaqMan microRNA Reverse Transcription Kit (Life Technologies). qRT-PCR analysis was performed on an Agilent MX3000P instrument. The primers for miR-140 and endogenous control RNU6B were purchased from Ambion. The gene expression (ΔCT) values of miRNA from each sample were calculated by normalizing to RNU6B, and relative quantitation (RQ) values were plotted.

For qRT-PCR analysis of mRNA expression, cDNA was synthesized using the PrimeScript RT Reagent Kit with gDNA Eraser (TaKaRa, Dalian, China). The qRT-PCR amplification for mRNA was performed with SYBR Premix Ex Taq II on an Agilent MX3000P instrument. The gene expression (ΔCT) values of mRNA from each sample were calculated by normalizing to GAPDH, and RQ values were plotted. Primers were used as follows:

**ADAMTS5:** (forward) 5′- AACTGCGGGTTCCCTGGGGTCCTGG -3′
(reverse) 5′- CATTTCCTGGCCTCACACTCTAT -3′

**IGFBP5:** (forward) 5′- GAGAGGGCGCAGAC -3′
(reverse) 5′- GCGAAGCCTCCATGTGTC -3′

**GAPDH:** (forward) 5′- GCACCGTCAAGGCTGAG -3′
(reverse) 5′- TGGTGAAGACGCCAGTGGA -3′

Protein extraction and Western blot
The parental and transfected cells were washed with prechilled PBS and lysed in 1 × RIPA buffer (Sigma, St. Louis). The protein concentration was measured by the Bradford method with BSA (Sigma) as the standard. Equal amounts of protein extract (50 μg) were denatured with 10% SDS-PAGE, transferred to PVDF membranes (Millipore), and blocked with 5% non-fat milk in TBST (0.1 M, pH 7.4). Protein abundance of GAPDH served as a control for protein loading. Each sample was treated with rabbit polyclonal anti-ADAMTS5 (1:250; Abcam) or mouse monoclonal anti-IGFBP5 (1:250; Abcam) primary antibodies at 4 °C overnight. Membranes were incubated with secondary antibodies, HRP-conjugated rabbit/mouse anti-IgG (LI-COR Biosciences), diluted at 1:16,000 in TBST, for 2 h at room temperature. Protein bands were detected by the Odyssey infrared imaging system (LI-COR Biosciences).

Immunohistochemistry analysis
CRC and normal colorectal tissues were sectioned into 4-μm thickness slides and were incubated with rabbit polyclonal anti-ADAMTS5 (1:50; Abcam) or mouse monoclonal anti-IGFBP5 (1:100; Abcam) overnight at 4 °C in a humidified container. Detection was determined by a Non-biotin Horseradish Peroxidase Detection System and DAB substrate (Dako).

All samples were observed by two pathologists. In case of a disagreement, the observers would re-examine and reach a consensus. For scoring expression of antibodies, both the intensity and extent of immunopositivity were considered. The dominant staining intensity in tumors was scored as follows: 0 = negative, 1 = weak, 2 = moderate, and 3 = strong. The extent of positive staining tumor cells was scored as follows: <25% = 1, 25–50% = 2, 51–75% = 3, and >75% = 4. The final score was determined by multiplying the intensity and the extent positivity scores, which yielded a range from 0 to 12. The mean score for each individual was calculated in tumor cells. The positive expression for markers was scored as follows: >1, IGFBP5 and >2, ADAMTS5. The positive expression of ADAMTS5 and IGFBP5 was found mainly on the cytoplasm of cells. They were presented as brown granular material.

Statistical analysis
Statistical analysis was performed using the SPSS software, version 11.0. The results were expressed as the mean ± standard deviation. Student's *t* test was used to determine the significance of two groups. Two matched clinical sample groups were analyzed by paired *t* test and two unpaired groups were analyzed by unpaired *t* test. One-way analysis of variance (ANOVA) followed by a Bonferroni-Dunn test was used to compare more than two groups. The correlation between miR-140 and ADAMTS5 or IGFBP5 expression was calculated using Spearman's correlation coefficient. The chi-square test was used to assess the associations among the positive staining of ADAMTS5 or IGFBP5 and clinicopathological indices. *P* < 0.05 was considered statistically significant.

Results
miR-140 expression is reduced in the CRC specimens, and its downregulation is associated with the tumor stage and metastasis
To determine the role of miR-140 in CRC development and progression, we evaluated the expressions of miR-140 in 60 paired CRC specimens and the corresponding normal colorectal tissues using qRT-PCR analysis. We found that miR-140 expression was significantly decreased in the CRC tissues compared with the normal controls (*P* = 0.037, Fig. 1).
All cases were then divided into a miR-140 low-expression group (n = 28) and a high-expression group (n = 32) using the median value as the cut off. The correlation between miR-140 expression and clinicopathological parameters was shown in Table 1. Our results indicated that miR-140 was negatively correlated with tumor stage (P = 0.045) and metastasis (P = 0.031). No significance was found for age, gender, or histological differentiation. These findings suggested that miR-140 may play a critical role in CRC development and progression.

**Table 1** The relationship between miR-140 expression and clinicopathological parameters in colorectal cancer

| Characteristics | No. of cases | miR-140 expression | P value |
|-----------------|--------------|---------------------|--------|
|                 |              | Low (median ≤0.278) | High (median >0.278) |
| Age             | 0.667        |                     |        |
| < 60 years      | 22           | 10                  | 12     |
| ≥60 years       | 38           | 18                  | 20     |
| Gender          | 0.778        |                     |        |
| Male            | 33           | 17                  |        |
| Female          | 27           | 12                  | 15     |
| Tumor size      | 0.602        |                     |        |
| < 5 cm          | 23           | 12                  | 11     |
| ≥5 cm           | 3 7 1 6 2 1  | 16                  | 21     |
| Stage           | 0.045*       |                     |        |
| I/II            | 28 1 27      | 1                   |        |
| III             | 32           | 27                  | 5      |
| Differentiation | 0.076        |                     |        |
| Well/moderate   | 24           | 13                  | 11     |
| Poor            | 36           | 15                  | 21     |
| Metastasis      | 0.031*       |                     |        |
| No              | 31 7 24      | 1                    |        |
| Yes             | 29 21 8      | 2                    |        |

**Fig. 1** miR-140 is decreased in CRC specimens. The qRT-PCR analysis of miR-140 was performed in 60 paired human CRC and the matched adjacent noncancerous tissues. Expression level of miR-140 was normalized by the internal control RNU6B in each sample. *P < 0.05

**ADAMTS5 and IGFBP5 are downregulated by miR-140 in HCT116 and RKO cells**

Bioinformatics analysis using the computational programs (microrna.org, targetscan.org, and pictar.mdc-berlin.de) has shown that the 3′-UTR of ADAMTS5 or IGFBP5 mRNA contains the putative binding sites of miR-140 (Fig. 2a). The later studies performed by Miyaki et al. [10] and Tardif et al. [38] have experimentally identified that ADAMTS5 and IGFBP5 are the direct targets of miR-140 in HEK293T cells or human OA chondrocytes. To further confirm that the expressions of ADAMTS5 and IGFBP5 are indeed regulated by miR-140 in CRC cells, we transiently transfected either miR-140 mimic or negative miRNA into HCT116 or RKO cells. The successful transfection of miR-140 was verified by qRT-PCR (Fig. 2b). The expressions of ADAMTS5 and IGFBP5 at both protein and mRNA levels were quantified by Western blot and qRT-PCR, respectively. We found that miR-140 inhibited the protein expressions (Fig. 2c) and decreased the mRNA levels of ADAMTS5 and IGFBP5 (Fig. 2d) in both HCT116 and RKO cells compared to the negative controls. Knockdown of ADAMTS5 and IGFBP5 by siRNAs were used as the positive control. These data indicated that ADAMTS5 and IGFBP5 expressions are regulated by miR-140 at the post-transcriptional level in the CRC cells, and this is consistent with the previous results [10, 38].

Next, we performed loss-of-function analysis to further confirm the regulation of ADAMTS5 and IGFBP5 by miR-140. The endogenous miR-140 was knocked down with inhibitor in HCT116 and RKO cells using lipofectamine 2000. To more accurately verify the regulation between miR-140 and ADAMTS5 or IGFBP5, we co-transfected miR-140 inhibitor and siRNA against ADAMTS5 or IGFBP5, respectively, into the CRC cells and considered it as a negative control. Meanwhile, lipofectamine 2000 alone and scrambled oligonucleotide of miRNA inhibitor were used as the negative control. We found that endogenous miR-140 knockdown can restore the expression of ADAMTS5 or IGFBP5 when compared to the negative controls using Western blot (Fig. 2e). All these results indicated that ADAMTS5 and IGFBP5 are downregulated by miR-140 in CRC cells.

**miR-140 inhibits the migratory and invasive capacities of CRC cells**

Given the clinical significance of miR-140 in the CRC specimens, we then assessed the impacts of miR-140 on the cell migration and invasion using scratch-wound and transwell chamber assays and determined the underlying
mechanism. In order to eliminate the effect of cell proliferation, CRC cells were cultured in the serum-free medium when performing the scratch-wound assay. As Fig. 3a showed, the gap was broader in the miR-140-transfection cells compared with the negative controls both in HCT116 and RKO cells, and the wound closure was also significantly inhibited by silenced ADAMTS5 or IGFBP5. The cell migratory capacity as assessed by transwell migratory assay (without matrigel) showed that miR-140 overexpression significantly decreased migration of the HCT116 cells compared with the negative controls (55.2 ± 7.5 vs. 107.2 ± 8.5 or 112.3 ± 6.1, \(P < 0.05\); Fig. 3b), while silenced ADAMTS5 (32.9 ± 3.8) or IGFBP5 (35.8 ± 2.6) had a similar effect with miR-140 overexpression (Fig. 3c). The results from RKO cells were consistent with the data from HCT116 cells (Fig. 3c). Together, miR-140 inhibits the capacities of migration and invasion of CRC cells in vitro, possibly through targeting of ADAMTS5 and IGFBP5.

Transwell invasion assay (with matrigel) showed that HCT116 cells with miR-140 overexpression penetrating through the membrane were remarkably less than those in the negative control groups (41.7 ± 4.5 vs. 83.2 ± 6.1 or 82.6 ± 7.9, \(P < 0.05\); Fig. 3c), while silenced ADAMTS5 (12.5 ± 3.2) or IGFBP5 (13.8 ± 2.6) had a similar effect with miR-140 overexpression (Fig. 3c). The results from RKO cells were consistent with the data from HCT116 cells (Fig. 3c). Together, miR-140 inhibits the capacities of migration and invasion of CRC cells in vitro, possibly through targeting of ADAMTS5 and IGFBP5.

Knockdown of miR-140 promotes the migratory and invasive capacities of CRC cells

So far we have assessed the significance of miR-140 in the CRC migration and invasion using a gain-in approach. In order to further elucidate the impacts of miR-140, we performed a series of knockdown experiments...
using miRNA inhibitors in HCT116 and RKO cells. As shown in Fig. 3d and e, antagonizing the endogenous miR-140 enhanced the CRC cell migratory potential compared to the negative controls using scratch-wound and transwell migration assays. Similarly, the cell invasion impact caused by endogenous miR-140 was reversed by knock down assay (Fig. 3f). These results are highly consistent with those obtained from exogenous miR-140 overexpression experiments. Thus, miR-140 impedes the migratory and invasive capacities of CRC cells in vitro, possibly via downregulating ADAMTS5 and IGFBP5.

ADAMTS5 and IGFBP5 are inversely correlated with the expression of miR-140 and enhance the progression and metastasis of CRC

Previously we confirmed that ADAMTS5 and IGFBP5 were downregulated by miR-140 in the CRC cell lines, and miR-140 expression was decreased in the CRC specimens as compared to the normal colorectal tissues. To further prove the regulatory interaction of miR-140 and ADAMTS5 and IGFBP5, we used qRT-PCR to measure the mRNA levels of ADAMTS5 and IGFBP5 in the same CRC cohort. The expressions of ADAMTS5 and IGFBP5 mRNA were dramatically increased in CRC specimens compared with adjacent normal tissues (Fig. 4a; $P < 0.05$), and the expression patterns were inversely correlated with that of miR-140 (Fig. 4b). These data in the clinical specimens further prove the negative regulatory interaction of miR-140 and ADAMTS5 and IGFBP5 concluded from the in vitro experiments.

We also performed immunohistochemistry to assess the expressions and clinical significance of ADAMTS5 and IGFBP5 proteins in the CRC cohort. As Fig. 4c showed, the positive percentages of ADAMTS5 and IGFBP5 expressions were 74.33% and 68.33%, respectively, in the primary CRC samples. When compared to the adjacent normal tissues (19.71% or 21.34%), the differences reached significance (both $P < 0.05$). These findings are consistent with the ADAMTS5 and IGFBP5 mRNA expressions, indicating that ADAMTS5 and IGFBP5 overexpression are related to the development of CRC.

Next, we analyzed the relationship of ADAMTS5 and IGFBP5 expression with the clinicopathological characteristics of the CRC patients. The results showed that overexpression of ADAMTS5 and IGFBP5 were positively correlated with the TNM stage and metastasis (all $P < 0.05$; Table 2). No significant correlation was found with the remaining parameters (Table 2). Taken together, these results suggest that the expression of ADAMTS5 and IGFBP5 is positively correlated with the progression and metastasis of CRC.
Discussion

The complications arising from metastasis become the major causes of death from cancer. In this study, we revealed a novel mechanism for the inhibition of miR-140 in the CRC progression through targeting ADAMTS5 and IGFBP5. Our interest in miR-140 was due to our previous study that indicates its effects on CRC cell proliferation and chemoresistance [13]. We reasoned that miR-140 may influence CRC progression and be a key regulator in CRC.

Firstly we observed a dramatic decrease in miR-140 in the CRC samples as compared to the adjacent normal tissues (Fig. 1). This is consistent with the results from our previous study [13] and a recent study [21]. More importantly, miR-140 downregulation was significantly associated with advanced clinical stage and distant metastasis of CRC (Table 1). In accordance with our results, Zhai et al. [21] found a more progressive reduction in miR-140 in the metastatic CRC tissues than in the primary tissues, and patients with high miR-140 expression had a much longer survival time, further supporting the inhibitory effect of miR-140 on the CRC metastasis.

miR-140 downregulation has also been verified in other solid cancers including HCC, NSCLC, and esophageal cancer [14–16], and miR-140 is negatively associated with tumor stage and metastasis of HCC and NSCLC.
The clinical relevance of miR-140 in these tumor samples indicates that miR-140 might be a critical regulator of cancer progression.

We next confirmed the inhibitory effects of miR-140 on the CRC cell migration and invasion in vitro (Fig. 3). Several studies have shown that miR-140 participates in the tumor invasion and metastasis through targeting TGFBR1, FGF9, IGF1R, MMD, and Slug [14–16]. In the current study, we confirmed that ADAMTS5 and IGFBP5 are downregulated by miR-140 in the CRC cell lines (Fig. 2). The inhibition of CRC cell migration and invasion by miR-140 is achieved possibly due to the suppression of ADAMTS5 or IGFBP5 (Fig. 3). Our clinical observations also showed that miR-140 has inverse correlation with ADAMTS5 or IGFBP5 (Fig. 4). Consistent with this, Güllü et al. [23] reported that, immunohistochemically, IGFBP5-negative breast cancer samples have a significantly increased expression of miR-140. However, their results indicated that miR-140 is dramatically increased in the breast cancer samples [23]. This different role of the same miRNA may depend on the types of cell and tissue, and time point [40]. A similar phenomenon exists in the stem cell proliferation. miR-140 inhibits breast or colorectal CSC survival and cancer invasive phenotype via downregulation of SOX2/9 or Smad2 [17–21], whereas, during embryonic bone development, miR-140 drives chondrocyte cell proliferation [8, 9] by targeting HDAC4 and the subsequent transcription of Runx2 [9]. This realization provides a captivating twist to the study of whole-organism functional genomics [40].

The role of ADAMTS5 in cancer has recently been investigated. However, little is known about its function in CRC. Kim et al. [41] reported that ADAMTS5 is highly methylated in CRC compared to the adjacent normal mucosa. On the contrary, our results showed that ADAMTS5 overexpression in the CRC specimen is associated with the TNM stage and metastasis (Table 2). Knockdown of ADAMTS5 can inhibit the CRC cell migration and invasion (Fig. 3). As a metalloproteinase, ADAMTS5 possibly promotes the CRC invasion and metastasis through breaking down the ECM, but further investigations are still required to help explain the function and underlying mechanism of ADAMTS5 in CRC.

Recent studies have demonstrated that IGFBP5 might be a useful biomarker for cancerous tissue and metastasis [31–37], but it also shows the opposite effect depending on cancer cell type and expression method [30, 43–46]. In colon cancer, a study using the rat model revealed that IGFBP5 is one of the top upregulated genes [35]. In accordance with this, we found that IGFBP5 serves as a cancer promoter based on our findings in the clinical CRC cohort and CRC cell lines (Figs. 3 and 4 and Table 2). Cell migration is a key step in the tumor metastasis process. Vitronectin (VN), a major ECM component, facilitates its function in diverse cellular processes such as cell migration and cell attachment through interactions with a number of ligands [47]. IGFBP5 has been confirmed to exert a stimulatory effect on cell migration when forming complexes with IGF-I and VN in skin keratinocytes and MCF7 breast cancer cells [48, 49]. Furthermore, Yasuoka et al. [50] suggested that IGFBP5 induces cell migration via MAPK-dependent and IGF-I-independent mechanisms.

### Table 2 Correlation between ADAMTS5 and IGFBP5 expression and clinicopathological characteristics in colorectal cancer

| Characteristic          | No. of cases | ADAMTS5 (+) | P value | IGFBP5 (+) | P value |
|-------------------------|--------------|-------------|---------|------------|---------|
| Age                     |              |             |         |            |         |
| < 60 years              | 22           | 14          | 0.467   | 16         | 0.378   |
| ≥ 60 years              | 38           | 18          | 0.564   | 20         | 0.867   |
| Gender                  |              |             |         |            |         |
| Male                    | 33           | 18          | 0.745   | 15         | 0.675   |
| Female                  | 27           | 14          |         | 13         |         |
| Tumor size              |              |             |         |            |         |
| < 5 cm                  | 23           | 13          | 0.041*  | 10         | 0.037*  |
| ≥ 5 cm                  | 37           | 19          |         | 18         |         |
| Stage                   |              |             |         |            |         |
| I/II                    | 28           | 3           | 0.027*  | 25         | 0.021*  |
| III/IV                  | 32           | 29          |         | 3          |         |
| Differentiation         |              |             |         |            |         |
| Well/moderate           | 24           | 15          | 0.896   | 9          | 0.18    |
| Poor                    | 36           | 17          |         | 19         |         |
| Metastasis              |              |             |         |            |         |
| No                      | 31           | 5           | 0.0467  | 26         | 0.037*  |
| Yes                     | 29           | 27          |         | 2          |         |

*P < 0.05

In summary, we experimentally prove that miR-140 inhibits CRC cell migration and invasion upon downregulating ADAMTS5 and IGFBP5. ADAMTS5 and IGFBP5 are overexpressed in the CRC specimens and are inversely correlated with the levels of miR-140. miR-140 downregulation and ADAMTS5 and IGFBP5 overexpression contribute to the TNM stage and metastasis of CRC. miR-140 might be a key regulator in CRC progression and metastasis and a potential therapeutic candidate for the treatment of CRC.
Abbreviations
ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs; CRC: Colorectal cancer; ECM: Extracellular matrix; EMT: Epithelial-mesenchymal transition; FBS: Fetal bovine serum; HCC: Hepatocellular carcinoma; IGFBP: Insulin-like growth factor-binding protein; miRNA: microRNA; MMD: Monocyte to macrophage differentiation-associated; NSCLC: Non-small cell lung cancer; OA: Osteoarthritis; PBS: Phosphate-buffered saline; qRT-PCR: Quantitative real-time polymerase chain reaction; RQ: Relative quantitation; siRNA: Small interfering RNA; VN: Vitronectin

Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 81172052 to BS), and from the ‘Yinggca’ program of Dalian Medical University to BS.

Funding
National Natural Science Foundation of China (No. 81172052 to BS).

Authors’ contributions
LY and YL conceived of and performed all the experiments, analyzed the data, and drafted the manuscript. XH was responsible for the molecular biology experiments. WZ performed the cell experiments and analyzed the data. JL revised the manuscript. JM analyzed the data. LL and MW analyzed the data. LL and JT revised the manuscript. BS conceived of the research, coordinated the study, interpreted the data, and revised the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All authors read and approved the final manuscript for publication.

Ethical approval and consent to participate
The use of human tissue samples was in accordance with relevant guidelines and regulations and the experimental protocols were approved by the Medical Ethics Committee of the First Affiliated Hospital of Dalian Medical University. All patients provided written informed consent prior to participation in this study.

Author details
1Department of Pathology, Dalian Medical University, No. 9 West Section, Lvshun South Road, Dalian 116044, People’s Republic of China. 2Teaching Laboratory of Morphology, Dalian Medical University, No. 9 West Section, Lvshun South Road, Dalian 116044, People’s Republic of China. 3Key Laboratory of Tumor Stem Cell Research of Liaoning Province, Dalian Medical University, No. 9 West Section, Lvshun South Road, Dalian 116044, People’s Republic of China. 4Key Laboratory of Tumor Metastasis Research of Liaoning Province, Dalian Medical University, No. 9 West Section, Lvshun South Road, Dalian 116044, People’s Republic of China.

Received: 5 July 2016 Accepted: 10 November 2016

References
1. Zheng ZX, Zheng RS, Zhang SW, Chen WQ. Colorectal cancer incidence and mortality in China. Asian Pac J Cancer Prev. 2014;15:8455–60.
2. Tang YL, Wang ZQ, Wang R, Ping J, Zhou ZG, Sun XF. The elderly patients colorectal cancer need careful multidisciplinary evaluation and optimizing comprehensive management. Int J Colorectal Dis. 2015;3:713–4.
3. Lianos GD, Glantzounis GK, Mangano A, Rausel S, Roukos DH. Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit? Future Oncol. 2014;10:723–6.
4. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol. 2010;7:251–65.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA target. Cell. 2005;121:1915–20.
6. Ambros V, Chen X. The regulation of genes and genomes by small RNAs. Development. 2007;134:1635–41.
7. Farazi TA, Hoell JL, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;737:1–20.
8. Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S, Plasterk RH. MicroRNA expression in zebrafish embryonic development. Science. 2005;309:310–1.
9. Tuddenham I, Wheeler G, Ntounia-Fousara S, Waters J, Hajhoseini I, Clark MK, Dalmay T. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 2006;580:4214–7.
10. Miyaki S, Sato T, Inoue A, Otsubi S, Ito Y, Yokoyama S, Kato Y, Tsuchimoto F, Nakata S, Yamashita S, Takada S, Lotz H, Ueno-Kudo MK, Asahara H. MicroRNA-140 plays dual roles in both cartilage development and homeostasis. Genes Dev. 2010;24:1173–85.
11. Zhang R, Ma J, Yao J. Molecular mechanisms of the stage-specific microRNA-140 in osteoarthritis. Inflamm Res. 2012;61:287–95.
12. Gibson G, Asahara H. microRNAs and cartilage. J Orthop Res. 2013;31:1333–44.
13. Song B, Wang Y, Yi Y, Kudo B, Bruheim S, Backchina GI, Ovvin E, Wan Y, Formentini A, Kommann M, Fostad B, Ju. Malignant chondrosarcoma-mediated by miR-140 in human cartilage and chondrosarcoma cancer cells. Oncogene. 2009;28:4065–74.
14. Yang H, Fang F, Chang R, Xie L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in colorectal carcinomas. Carcinogenesis. 2013;34:205–17.
15. Li W, He F. MicroRNA to macrophage differentiation-associated (MMD) targeted by miR-140 inhibits colorectal cancer cell growth. Biochem Biophys Res Commun. 2014;450:844–50.
16. Li W, Ji J, Zhou H, Li Y, Zou H, Yuan J. Down-regulation of miR-140 induces EMAT and promotes invasion by targeting α-SMA in stage4 pulmonary cell. Cell Physiol Biochem. 2014;33:1466–76.
17. Zhang Y, Eades G, Yao Y, Li Q, Zhou Q. Estrogen receptor α signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. J Biol Chem. 2012;287:41514–22.
18. Liu R, Yao Y, Eades G, Liu Z, Zhang Y, Zhou Q. Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene. 2014;33:2589–600.
19. Woflson B, Eades G, Zhou Q. Roles of microRNA-140 in stem cell-associated early stage breast cancer. World J Stem Cells. 2014;6:591–7.
20. Gennapudi R, Yao Y, Zhang Y, Woflson B, Roy S, Dura N, Eades G, Yang P, Zhou Q. Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer. Breast Cancer Res Treat. 2015;150:685–95.
21. Zhai H, Fesler A, Ba Y, Wu S, Ju J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget. 2015;6:19735–46.
22. Malkowski B, Wolter M, Liesenberg F, Girzdnowski M, Stühler K, Meyer HE, Reifenberger G. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20:539–50.
23. Güllü G, Peker I, Haholu A. Clinical significance of miR-140-5p and miR-193b expression in patients with breast cancer and relationship to IGFBP5. Genet Mol Biol. 2015;38:321–9.
24. Rooks NC, Paulissen G, El Hour M, Queama F, Crayh C, Guedes M, Foidart JM, Noel A, Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90:369–79.
25. Nakada M, Miyamori H, Kita D, Takahashi T, Yamashita J, Sato H, Miura R, Yamaguchi Y, Okada Y. Human gliblastomas overexpress ADAMTS-5 that degrades brevacan, Acta Neuropathol. 2005;110:239–46.
26. Demirkan K, Gunduz E, Gunduz M. Increased mRNA expression of ADAMTS metalloproteinases in metastatic foci of head and neck cancer. Head Neck. 2009;31:793–801.
27. Filou S, Stylianou M, Triantaphyllidou IE, Papadas T, Mastronikolis NS, Goumas PD, Papachristos DJ, Ravazoula P, Skandalis SS, Vynios DH. Expression and distribution of aggrecanases in human larynx: ADAMTS-5/IGFBP-5: a critical member of the IGF axis. Biochem J. 2001;359:265–75.
28. Zhang J, Qin X, Sun Q, Guo H, Wu X, Xie F, Xu Q, Yan M, Liu J, Han Z, Chen W. Transcriptional control of PAX4-regulated miR-144-451 modulates metastasis by suppressing ADAMs expression. Oncogene. 2015;34:2382–95.
29. Beattei J, Allan GJ, Loichie JD. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395:1–19.
30. Güllü G, Karabultu S, Akkiprik M. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer. 2012;31:266–80.

31. Gregory CW, Kim D, Ye P, Ercole AJ, Pretlow TG, Mohler JL, French FS. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft. Endocrinology. 1999;140:2372–81.

32. Miyakoshi N, Richman C, Qin X, Baylink DJ, Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology. 1999;140:5719–28.

33. Miyakoshi N, Richman C, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that IGF-binding protein-5 functions as a growth factor. J Clin Invest. 2001;107:73–81.

34. Pittini SJ, Faca VM, Kelly-Spratt KS. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res. 2008;7:1481–9.

35. Femia AP, Luceri C, Toti S, Giannini A, Dolara P, Caderni G. Gene expression profile and genomic alterations in colorectal tumours induced by 1,2-dimethyhydrazine (DMH) in rats. BMC Cancer. 2010;10:194.

36. Hao X, Sun B, Hu L, Lähdesmäki H, Dunmire V, Feng Y. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer. 2004;100:1110–22.

37. Wang H, Arun BK, Wang H, Fuller GN, Zhang W, Middleton LP, Sahin AA. IGFBP2 and IGFBPs overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J. 2008;14:261–7.

38. Tardif G, Hurn D, Pellerier JP, Duval N, Martel-Pelletier J. Regulation of the IGFBP-5 and MMP-13 genes by the microRNAs miR-140 and miR-27a in human osteoarthritic chondrocytes. BMC Musculoskel Disord. 2009;10:148–58.

39. Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K, Ju J. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer. 2011;10:340–7.

40. Green D, Dalmay T, Fraser WD. Role of miR-140 in embryonic bone development and cancer. Clin Sci (Lond). 2015;129:863–73.

41. Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, Min BH, Kim DH, Son JS, Park KY, Kim JS, Jhee JC, Kim HC, Chun HK, Grady WM, Kim YS. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol. 2013;20:2338–47.

42. Wagstaiff L, Kelwick R, Decock J, Edwards DR. The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front Biosci (Landmark Ed). 2011;16:1861–72.

43. Sureshbabu A, Okajima H, Yamakawa D. IGFBPs induce epithelial adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci. 2012;125:1693–703.

44. Luther GA, Lamplot J, Chen X, You S, Wang ER, Liu X, Parekh A, Huang E, Kim SH, Shen J, Haydon RC, He TC, Luu HH. IGFBP3 domains exert distinct inhibitory effects on the tumor growth and metastasis of human osteosarcoma. Cancer Lett. 2013;327:222–30.

45. Vijayan A, Guha D, Ameer F, Kaziri I, Mooney CC, Bennett L, Sureshbabu A, Tonton E, Burke S, Shroyer K, Ju J. Edwards DR. IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFβ-induced mesenchymal invasion. J Biol Chem. 2013;288:2774–85.

46. Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, Deng Y, Yang Y, Li Y, Ruan X, Xie F, Zhao H, Fang X. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncogenesis. 2015;4:e20636–49.

47. Yang W, Wu J, Spong S, Sheddard D. The integrin alphavbeta5 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Biol. 1998;141:2189–95.

48. Hyde C, Hollier B, Anderson A. Insulin-like growth factors (IGF) and IGF-binding proteins bound to vitronectin enhance keratinocyte protein synthesis and migration. J Invest Dermatol. 2004;122:1198–205.

49. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z. Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology. 2003;144:2807–15.

50. Yasuoka H, Hsu E, Ruiz XD, Steinman RA, Choi AM, Feghali-Bostwick CA. The fibrotic phenotype induced by IGFBP-5 is regulated by MAPK activation and egr-1-dependent and -independent mechanisms. Am J Pathol. 2009;175:605–15.